LMNA and familial dilated cardiomyopathy: According to currentguidelines, the prevention of SCD through an implantablecardioverter-defibrillator (ICD) is recommended either for individuals withreduced left ventricular ejection fraction (LVEF) (≤35%) and symptomaticheart failure or for DCM patients with a detected disease-causing mutations inlamin A/C (LMNA) gene and additional risk factors.